Prosecution Insights
Last updated: November 16, 2026
Application No. 18/602,115

Therapy Applicator Head

Final Rejection §103
Filed
Mar 12, 2024
Priority
Feb 04, 2024 — CN 2024202799323 +1 more
Examiner
LAU, MICHAEL J
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Shenzhen Nuon Medical Equipment Co. Ltd.
OA Round
2 (Final)
72%
Grant Probability
Favorable
3-4
OA Rounds
95%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
237 granted / 327 resolved
+2.5% vs TC avg
Strong +23% interview lift
Without
With
+22.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
38 currently pending
Career history
366
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant’s arguments, see pages 8-31, filed 8/5/2026, with respect to the rejection(s) of claim(s) 1-20 under USC 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Ignon (US 8048089 B2) in view of Sedic (US 10307330 B1), further in view of Hung (US 2014/0378555 A1), further in view of Browne (US 2015/0051671 A1). Claim Rejections – 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-4, 7-10, and 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ignon (US 8048089 B2) in view of Sedic (US 10307330 B1), further in view of Hung (US 2014/0378555 A1), further in view of Browne (US 2015/0051671 A1). Regarding claim 1, Ignon discloses a therapy applicator head (eg. Fig. 2A-B applicator with main body 30 and tip 34), the therapy applicator head comprising: a housing container comprising an applicator body (eg. Fig. 2A-B, main body 30); an applicator plate provided in an upper portion of the applicator body, the applicator plate inclined at a predetermined angle (eg. Fig. 2A-B, flat surface distal end 102 at an angle, Col. 6, Ln. 38-50); one or more stimulation elements located underneath the applicator plate (eg. Col. 5, Ln. 9-35, Col. 18, Ln. 14-51); and a rechargeable electrical power source located below the applicator plate (eg. Fig. 18-19 Col. 19, Ln. 35-56), the rechargeable electrical power source configured to supply electrical power to the one or more electrical components such as valves/pumps (eg. Fig. 18-19 Col. 19, Ln. 35-56), wherein the applicator plate further comprises a dispensing hole located in an uphill portion on an upper surface of the applicator plate, the dispensing hole configured to be fluidically connected to a serum container through a fluidic channel (eg. Fig. 3 Col. 7, Ln. 45 – Col. 8, Ln. 20), and wherein, in use, a serum contained in the serum container is configured to flow downhill from the dispensing hole and along the inclined applicator plate (eg. Col. 13, Ln. 15-40, Col. 15, Ln. 25 – Col. 16, Ln 45). Ignon does not explicitly disclose a rechargeable electrical power supply for stimulation elements, electrically coupled to a first housing printed circuit board located underneath the applicator plate the rechargeable electrical power source configured to receive electrical power through at least two charging terminals, and wherein the at least two charging terminals are electrically coupled to the first housing printed circuit board and flush with the upper surface of the applicator plate, the at least two charging terminals configured to receive electrical power to charge the rechargeable electrical power source. Sedic teaches a skincare device that uses rechargeable batteries to power light sources for light stimulation therapy (eg. Col. 9, Ln. 60 – Col. 10, Ln. 40). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the invention of Ignon to have the rechargeable power source provide power to stimulation elements as taught by Sedic because stimulation elements in the art commonly need a power source for them to work by default and it would provide the predictable result of providing power to provide a cordless option for the device if desired. Hung teaches a therapy device that has surface electrodes on its face that can be used for both delivering stimulation and charging the rechargeable battery (eg. Para. 77, Fig 6 and 26-27, electrodes 261 and 262 connected to the circuit board 263). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention of Ignon and Sedic to have modified the invention to have the stimulation electrodes to also have charging capabilities for a rechargeable battery as taught by Hung to provide the predictable result of not needing to add an additional charging connector (eg. Hung, Para. 77). Browne teaches an applicator with an applicator plate and back plate with a PCB underneath the applicator plate (Eg. Para. 16, 48, 51). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the invention of Ignon, Sedic, and Hung with the PCB layered right underneath the plate since it would have been obvious to rearrange the parts as a design choice for the predictable result of having contact with the electrodes and making the applicator more compact. Regarding claim 2, the combined invention of Ignon, Sedic, Hung, and Browne discloses the applicator plate is made from a thermally conducting material and/or an electrically conducting material (eg. Ignon, Sedic, Col. 5, Ln. 60 – Col. 6, Ln. 38, Col. 8, Ln. 39 – Col. 9, Ln. 22, Col. 13, Ln. 44 – Col. 14, Ln. 24). Regarding claim 3, the combined invention of Ignon, Sedic, Hung, and Browne discloses the predetermined angle of the applicator plate is adjustable (eg. Ignon, Col. 6, Ln. 10-50, one of ordinary skill could change an angle of the plate to suit design choices, see MPEP 2144.05). Regarding claim 4, the combined invention of Ignon, Sedic, Hung, and Browne discloses the first housing printed circuit board comprises the at least two charging terminals (Eg. Hung, Para. 77, contacts 261 and 262 connected to circuits 263/265). Regarding claim 7, the combined invention of Ignon, Sedic, Hung, and Browne discloses the housing container comprises a first engaging arrangement configured to engage with a second engaging arrangement of the serum container, the second engaging arrangement complementary to the first engaging arrangement, to fasten the housing container to the serum container (eg. Fig. 18-19, Col. 19, Ln. 35 – Col. 20, Ln. 10). Regarding claim 8, the combined invention of Ignon, Sedic, Hung, and Browne discloses the one or more stimulation elements are selected from a group consisting of irradiation sources, heating elements, cooling elements, vibratory elements, ultrasonic wave generators, electrodes, and combinations thereof (eg. Ignon, Col. 5, Ln. 9-21, Col. 18, Ln. 14-38). Regarding claim 9, the combined invention of Ignon, Sedic, Hung, and Browne discloses the irradiation sources are configured to emit electromagnetic radiation in wavelengths ranging between 300 nm and 1200 nm (eg. Ignon, Col. 5, Ln. 9-21, Col. 18, Ln. 14-38). Regarding claim 10, the combined invention of Ignon, Sedic, Hung, and Browne discloses a user interface configured to receive control input signals to modify operational characteristics of the one or more stimulation elements (eg. Ignon, Col. 2, Ln. 8-17, Col. 17, Ln. 45-63 and Sedic, Col. 11, Ln. 55 – Col. 12, Ln. 25). Regarding claim 18, the combined invention of Ignon, Sedic, Hung, and Browne discloses a method of using a therapy applicator head, the method comprising: providing the therapy applicator head (eg. Ignon Fig. 2A-B applicator with main body 30 and tip 34), the therapy applicator head comprising: a housing container comprising an applicator body (eg. Ignon, Fig. 2A-B, main body 30), an applicator plate provided in an upper portion of the applicator body (eg. Ignon, Fig. 2A-B, flat surface distal end 102 at an angle, Col. 6, Ln. 38-50), the applicator plate inclined at a predetermined angle (eg. Ignon, Fig. 2A-B, flat surface distal end 102 at an angle, Col. 6, Ln. 38-50), one or more stimulation elements located underneath the applicator plate (eg. Ignon, Col. 5, Ln. 9-35, Col. 18, Ln. 14-51), and electrically coupled to a first housing printed circuit board located underneath the applicator plate (eg. Browne, Para. 16, 48, 51) a rechargeable electrical power source located below the applicator plate, the rechargeable electrical power source configured to receive electrical power through at least two charging terminals (eg. Hung Para. 77) and supply electrical power to the one or more stimulation elements (eg. Ignon, Fig. 18-19 Col. 19, Ln. 35-56), and at least two charging terminals electrically coupled to the first housing printed circuit board and flush with an upper surface of the applicator plate (eg. Hung, Para. 77), the at least two charging terminals configured to receive electrical power to charge the rechargeable electrical power source (eg. Ignon, Fig. 18-19 Col. 19, Ln. 35-56 and eg. Sedic, Col. 9, Ln. 60 – Col. 10, Ln. 40); fastening the housing container to a serum container (eg. Ignon, Col. 19, Ln. 35-56, Fig. 18-19, Col. 5, Ln. 35 – Col. 6, Ln. 10, Col. 14, Ln. 4 – Col. 15, Ln. 2, manifold system holding containers), the housing container comprising a first engaging arrangement configured to engage with a second engaging arrangement of the serum container, the second engaging arrangement complementary to the first engaging arrangement (eg. Ignon, Col. 19, Ln. 35-56, Fig. 18-19, Col. 5, Ln. 35 – Col. 6, Ln. 10, Col. 14, Ln. 4 – Col. 15, Ln. 2, Col. 9, Ln. 17-60, manifold system holding containers, screws/threading and other commonly used attachment mechanisms may be used, see MPEP 2144.05), wherein the applicator plate further comprises a dispensing hole on the upper surface of the applicator plate (eg. Col. 7, Ln. 45 – Col. 8, Ln. 20), the dispensing hole fluidically connected to the serum container through a fluidic channel; applying the applicator plate to a body portion of a user (eg. Ignon, Col. 7, Ln. 45 – Col. 8, Ln. 20, Col. 10, Ln. 55-67), as a result wherein, a serum stored in the serum container is applied, to the body portion of the user, through the fluidic channel (eg. Ignon, Col. 7, Ln. 45 – Col. 8, Ln. 20, Col. 10, Ln. 55-67); and activating the one or more stimulation elements (eg. Ignon, Col. 5, Ln. 9-35, Col. 18, Ln. 14-51 and Sedic, Col. 9, Ln. 60 – Col. 10, Ln. 40) through a user interface configured to receive control input signals to modify operational characteristics of the one or more stimulation elements (eg. Col. 17, Ln. 45-64). Claim(s) 5-6, 15-17, and 19-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ignon (US 8048089 B2) in view of Sedic (US 10307330 B1), further in view of Hung (US 2014/0378555 A1), further in view of Browne (US 2015/0051671 A1), further in view of Greuel (US 9045358 B2). Regarding claims 5 and 19, the combined invention of Ignon, Sedic, Hung, and Browne discloses the invention of claim 4, but does not disclose a removable cap configured to be fastened onto the housing container, wherein the removable cap comprises enclosed therewithin at least two power terminals configured to make contact with the at least two respective charging terminals, to supply electrical power to the at least two charging terminals from an external power source. Greuel teaches a cylinder with a removable cap with a built in UV radiation light for disinfecting the contents inside (eg. Fig. 1, cap 14, Col. 5, Ln. 40 – Col. 6, Ln. 40). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the invention of Ignon, Sedic, Hung, and Browne that uses silicone covers (eg. Col. 22, Ln. 13-47, silicone covers, one of ordinary skill would use any covers or caps appropriate to cover the charging terminals since covers for those are common in the art for preventing shorting and other damage to the electronics) with the UV cap as taught by Greuel since caps and coverings are common in the art and the UV light would provide the predictable result of sterilizing the contact surface to prevent infections. Regarding claims 6 and 20, the combined invention of Ignon, Sedic, Hung, Browne, and Greuel discloses the removable cap and the one or more stimulation elements comprise an Ultraviolet (UV) light source configured to sterilize the upper surface of the applicator plate (eg. Greuel, cap 14, Col. 5, Ln. 40 – Col. 6, Ln. 40) when the removable cap is fastened onto the housing container (one of ordinary skill would have done the sterilization when the cap is fastened for the predictable result of preventing shorting and other damage to electronics). Regarding claim 15, the combined invention of Ignon, Sedic, Hung, Browne, and Greuel discloses a therapy applicator head, the therapy applicator head comprising (eg. Ignon Fig. 2A-B applicator with main body 30 and tip 34): a housing container comprising an applicator body (eg. Ignon, Fig. 2A-B, main body 30); an applicator plate provided in an upper portion of the applicator body (eg. Ignon, Fig. 2A-B, flat surface distal end 102 at an angle, Col. 6, Ln. 38-50); one or more stimulation elements located underneath the applicator plate (eg. Ignon, Col. 5, Ln. 9-35, Col. 18, Ln. 14-51) , and electrically coupled to a first housing printed circuit board located underneath the applicator plate (eg. Browne, 16, 48, 51); a rechargeable electrical power source located below the applicator plate (eg. Ignon, Fig. 18-19 Col. 19, Ln. 35-56), the rechargeable electrical power source configured to receive electrical power through at least two charging terminals (eg. Hung, Para. 77) and supply electrical power to the one or more stimulation elements (eg. Ignon, Fig. 18-19 Col. 19, Ln. 35-56 and eg. Sedic, Col. 9, Ln. 60 – Col. 10, Ln. 40); at least two charging terminals electrically coupled to the first housing printed circuit board and flush with an upper surface of the applicator plate (eg. Hung, Para. 77), the at least two charging terminals configured to receive electrical power to charge the rechargeable electrical power source source (eg. Ignon, Col. 19, Ln. 35-56, AC power supply with positive and negative); and a removable cap configured to be fastened onto the housing container, wherein the removable cap comprises enclosed a cap body enclosing a cap printed circuit board, a power receiving terminal configured to receive electrical power from an external electrical power source (Eg. Hung, Para. 77 and Browne, Para. 16, 48, 51, one of ordinary skill could rearrange the parts to have the pcb since it will have the same function of receiving external electrical power, see MPEP 2144.04), and at least two power terminals electrically coupled to the cap printed circuit board and configured to make contact with the at least two respective charging terminals flush with the upper surface of the applicator plate, to supply electrical power to the at least two charging terminals from an external power source (eg. Fig. 1, cap 14, Col. 5, Ln. 40 – Col. 6, Ln. 40, Eg. Hung, Para. 77 and Browne, Para. 16, 48, 51). Regarding claim 16, the combined invention Ignon, Sedic, Hung, Browne, and Greuel discloses the applicator plate inclined at a predetermined angle, the predetermined angle of the applicator plate being adjustable (eg. Ignon, Col. 6, Ln. 10-50, one of ordinary skill could change an angle of the plate to suit design choices, see MPEP 2144.05). Regarding claim 17, the combined invention Ignon, Sedic, Hung, Browne, and Greuel discloses the removable cap and the one or more stimulation elements comprise an Ultraviolet (UV) light source configured to sterilize the upper surface of the applicator plate. (eg. Greuel, cap 14, Col. 5, Ln. 40 – Col. 6, Ln. 40). Claim(s) 11-13 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ignon (US 8048089 B2) in view of Sedic (US 10307330 B1), further in view of Hung (US 2014/0378555 A1), further in view of Browne (US 2015/0051671 A1), further in view of Gavini (US 2016/0354559 A1). Regarding claim 11, the combined invention of Ignon, Sedic, Hung, and Browne discloses a processor; a memory unit operably connected with a processor (eg. Ignon, Col. 17, Ln. 45-65); but does not disclose a pressure sensor mechanically coupled to the applicator plate, wherein the memory unit comprises machine-readable instructions, the machine-readable instructions when executed by the processor, enable the processor to: receive a pressure input from the pressure sensor, indicative of a predetermined amount of pressure applied onto the applicator plate, and allow the serum to be dispensed from the dispensing hole in response to sensing the predetermined amount of pressure. Gavini teaches a handheld fluid delivery device that activates via a pressure sensor when contact is made with the skin (eg. Para. 3, 57). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the invention of Ignon, Sedic, Hung, and Browne with the pressure sensor activation as taught by Gavini as pressure sensor activation mechanisms are commonly used in the art and would provide the predictable result of increasing efficiency of only activating a treatment when there is contact with the skin. Regarding claim 12, the combined invention of Ignon, Sedic, Hung, Browne, and Gavini discloses the processor is further enabled to operate an electronically controlled valve to allow the serum to be dispensed from the dispensing hole (eg. Col. Ignon, 5, Ln. 44-60, Col. 8, Ln. 49-62, Col. 18, Ln. 57 – Col. 19, Ln. 9). Regarding claim 13, the combined invention of Ignon, Sedic, Hung, Browne, and Gavini discloses the processor is further enabled to operate an electronically controlled pump to allow the serum to be dispensed from the dispensing hole (eg. Col. Ignon, 5, Ln. 44-60, Col. 8, Ln. 49-62, Col. 18, Ln. 57 – Col. 19, Ln. 9). Claim(s) 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Ignon (US 8048089 B2) in view of Sedic (US 10307330 B1), further in view of Hung (US 2014/0378555 A1), further in view of Browne (US 2015/0051671 A1), further in view of Gavini (US 2016/0354559 A1), further in view of Bernstein (US 91139836 B2). Regarding claim 14, the combined invention of Ignon, Sedic, Hung, Browne, and Gavini discloses the invention of claim 11, but does not disclose a skin condition sensor mechanically coupled to the applicator plate, wherein the processor is further enabled to: receive skin condition data from the skin condition sensor, and in correlation with the skin condition data, perform one or more of: modifying operational characteristics of the one or more stimulation elements, and allowing a predetermined amount of serum to be dispensed from the dispensing hole. Bernstein teaches a device for scanning skin conditions and providing therapies (eg. Abstract, Col. 1, Ln. 59 – Col. 2, Ln. 38, Col. 6, Ln. 7-25, sensor 295, Col. 10, Ln. 61 – Col. 13, Ln. 19, Col. 47, Ln. 50 – Col. 48, Ln. 13). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have combined the invention of Ignon, Sedic, Hung, Browne and Gavini with the skin condition sensor mechanism as taught by Bernstein since both inventions relate to treating skin conditions and would further enhance the processor controlled pumps/valves in Ignon to provide the predictable result of identifying and treating only affected tissue. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL J LAU whose telephone number is (571)272-2317. The examiner can normally be reached 8-5:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Hamaoui can be reached at 5712705625. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL J LAU/Examiner, Art Unit 3796
Read full office action

Prosecution Timeline

Mar 12, 2024
Application Filed
May 14, 2026
Non-Final Rejection mailed — §103
Aug 05, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788301
Systems, Methods, and Computer Program Products for Improved Cardiac Diagnosis And/or Monitoring With ECG Signals
3y 0m to grant Granted Nov 10, 2026
Patent 12788506
System And Method For Reducing Tool Vibration At A Variable Stiffness End Effector Of A Surgical System
2y 7m to grant Granted Nov 10, 2026
Patent 12773143
Method for Improving the Success of Immediate Wellbeing Interventions to Achieve a Desired Emotional State
5y 0m to grant Granted Oct 27, 2026
Patent 12773115
SYSTEMS AND METHODS FOR PREDICTING AND PREVENTING CASES OF SUDDEN UNEXPECTED INFANT DEATH CAUSED BY SUDDEN UNEXPECTED POSTNATAL COLLAPSE
3y 1m to grant Granted Oct 27, 2026
Patent 12773152
APPARATUS FOR GENERATING AN ELECTROCARDIOGRAM
2y 7m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
72%
Grant Probability
95%
With Interview (+22.8%)
Moderate
PTA Risk
Based on 327 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month